Aclaris Therapeutics Inc (NASDAQ: ACRS) on Friday, soared 15.47% from the previous trading day, before settling in for the closing price of $1.81. Within the past 52 weeks, ACRS’s price has moved between $0.59 and $5.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 74.29%. The company achieved an average annual earnings per share of 56.36%. With a float of $67.49 million, this company’s outstanding shares have now reached $70.89 million.
Let’s determine the extent of company efficiency that accounts for 91 employees. In terms of profitability, gross margin is 65.56%, operating margin of -193.06%, and the pretax margin is -184.43%.
Aclaris Therapeutics Inc (ACRS) Insider Activity
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Aclaris Therapeutics Inc is 5.40%, while institutional ownership is 72.99%. The most recent insider transaction that took place on Aug 05 ’24, was worth 256,357. In this transaction 10% Owner of this company bought 206,025 shares at a rate of $1.24, taking the stock ownership to the 14,250,000 shares. Before that another transaction happened on Aug 02 ’24, when Company’s 10% Owner bought 167,544 for $1.29, making the entire transaction worth $216,400. This insider now owns 14,043,975 shares in total.
Aclaris Therapeutics Inc (ACRS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 56.36% per share during the next fiscal year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Aclaris Therapeutics Inc (ACRS) is currently performing well based on its current performance indicators. A quick ratio of 7.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.83, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Looking closely at Aclaris Therapeutics Inc (NASDAQ: ACRS), its last 5-days average volume was 1.12 million, which is a jump from its year-to-date volume of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 89.77%. Additionally, its Average True Range was 0.12.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 96.15%, which indicates a significant increase from 95.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 120.71% in the past 14 days, which was higher than the 68.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.25, while its 200-day Moving Average is $1.22. However, in the short run, Aclaris Therapeutics Inc’s stock first resistance to watch stands at $2.22. Second resistance stands at $2.36. The third major resistance level sits at $2.58. If the price goes on to break the first support level at $1.86, it is likely to go to the next support level at $1.64. Should the price break the second support level, the third support level stands at $1.50.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
Market capitalization of the company is 172.18 million based on 71,345K outstanding shares. Right now, sales total 31,250 K and income totals -88,480 K. The company made 2,770 K in profit during its latest quarter, and -10,990 K in sales during its previous quarter.
